Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results

GuruFocus.com03-20

Financial Position: Tango Therapeutics Inc (NASDAQ:TNGX) ended 2023 with a robust cash position of $337 million, expected to fund operations into late 2026. Revenue: Collaboration revenue for Q4 2023 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2420971582?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CLBAKvKezeYK9xzd417sdQ--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/95ccf3f0641f5bf4b629d8138913eb2e","is_english":true,"pubTime":"2024-03-20 17:31","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2420971582","market":"us","top_or_hot":-1,"title":"Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results","media":"GuruFocus.com","content":"<div>\n<p>Financial Position: Tango Therapeutics Inc (NASDAQ:TNGX) ended 2023 with a robust cash position of $337 million, expected to fund operations into late 2026.\nRevenue: Collaboration revenue for Q4 2023 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tango-therapeutics-inc-tngx-reports-093158318.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-20 17:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tango-therapeutics-inc-tngx-reports-093158318.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Financial Position: Tango Therapeutics Inc (NASDAQ:TNGX) ended 2023 with a robust cash position of $337 million, expected to fund operations into late 2026.\nRevenue: Collaboration revenue for Q4 2023 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tango-therapeutics-inc-tngx-reports-093158318.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QID","symbol_name":"纳指两倍做空ETF","start_time":0,"source_url":"https://finance.yahoo.com/news/tango-therapeutics-inc-tngx-reports-093158318.html","article_id":"2420971582","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CLBAKvKezeYK9xzd417sdQ--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/95ccf3f0641f5bf4b629d8138913eb2e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2420971582","pubTimestamp":1710927118,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Financial Position: Tango Therapeutics Inc  ended 2023 with a robust cash position of $337 million, expected to fund operations into late 2026.Revenue: Collaboration revenue for Q4 2023 was $5.4 million, down from $6.4 million in Q4 2022, with full-year revenue increasing to $31.5 million from $24.9 million year-over-year.Net Loss: Q4 2023 net loss was $30.8 million, or $0.32 per share, an improvement from a net loss of $29.1 million, or $0.33 per share, in Q4 2022.R&D Expenses: Research and development expenses increased to $31.3 million in Q4 2023, up from $29.1 million in the same period last year.GuruFocus has detected 3 Warning Sign with TNGX.On March 18, 2024, Tango Therapeutics Inc  released its 8-K filing, detailing the company's financial results for the fourth quarter and the full year ended December 31, 2023. The biotechnology firm, which focuses on precision oncology treatments, reported a strong cash position and progress in its clinical trials.Tango Therapeutics Inc  is a","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"QID":"纳指两倍做空ETF","QLD":"纳指两倍做多ETF","SQQQ":"纳指三倍做空ETF","QQQ":"纳指100ETF","TQQQ":"纳指三倍做多ETF","TNGX":"Tango Therapeutics Inc.",".IXIC":"NASDAQ Composite","BK4139":"生物科技","PSQ":"纳指反向ETF"},"translate_title":"探戈治疗公司（TNGX）报告全年和2023年第四季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNGX":1,".IXIC":0.9,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"Financial Position: Tango Therapeutics Inc (NASDAQ:TNGX) ended 2023 with a robust cash position of $337 million, expected to fund operations into late 2026.\nRevenue: Collaboration revenue for Q4 2023 was $5.4 million, down from $6.4 million in Q4 2022, with full-year revenue increasing to $31.5 million from $24.9 million year-over-year.\nNet Loss: Q4 2023 net loss was $30.8 million, or $0.32 per share, an improvement from a net loss of $29.1 million, or $0.33 per share, in Q4 2022.\nR&D Expenses: Research and development expenses increased to $31.3 million in Q4 2023, up from $29.1 million in the same period last year.\nOperational Milestones: Tango Therapeutics Inc (NASDAQ:TNGX) dosed the first patient in the phase 1/2 clinical trial for TNG348 and received FDA Orphan Drug Designation for TNG462.\n\n\nWarning! GuruFocus has detected 3 Warning Sign with TNGX.\n\n\nOn March 18, 2024, Tango Therapeutics Inc (NASDAQ:TNGX) released its 8-K filing, detailing the company's financial results for the fourth quarter and the full year ended December 31, 2023. The biotechnology firm, which focuses on precision oncology treatments, reported a strong cash position and progress in its clinical trials.\nCompany Overview\nTango Therapeutics Inc (NASDAQ:TNGX) is a clinical-stage biotechnology company dedicated to developing precision oncology therapies. Its pipeline includes TNG908, a PRMT5 inhibitor for MTAP-deleted solid tumors, and other discovery programs such as TNG462, TNG348, and TNG260 targeting various cancer types with limited treatment options.\nFinancial Performance and Challenges\nThe company's financial health is underscored by a strong cash position of $337 million as of December 31, 2023, bolstered by an additional $42 million from an at-the-market (ATM) offering in January 2024. This positions Tango Therapeutics Inc (NASDAQ:TNGX) to fund all clinical programs through proof-of-concept into late 2026. However, the company faces the inherent challenges of the biotechnology industry, including the high costs of research and development, the need for regulatory approvals, and the uncertainty of clinical trial outcomes.\nFinancial Achievements and Industry Significance\nThe company's achievements, such as the FDA Orphan Drug Designation for TNG462 and the initiation of the phase 1/2 clinical trial for TNG348, are significant milestones. These developments not only validate the company's research but also offer potential competitive advantages in the oncology market.\nKey Financial Metrics\nCollaboration revenue for the fourth quarter of 2023 was $5.4 million, a slight decrease from $6.4 million in the same period in 2022. However, the full-year collaboration revenue increased to $31.5 million in 2023 from $24.9 million in 2022. Research and development expenses rose to $31.3 million in the fourth quarter, reflecting the company's investment in advancing its clinical pipeline. General and administrative expenses also increased to $9.1 million in the fourth quarter, up from $7.9 million in the prior year's quarter. The net loss for the fourth quarter was $30.8 million, or $0.32 per share, an improvement over the net loss of $29.1 million, or $0.33 per share, in the fourth quarter of 2022.\nAnalysis of Performance\nThe company's increased R&D spending is indicative of its commitment to advancing its clinical programs. The management's commentary, as quoted by President and CEO Barbara Weber, M.D., highlights the strategic progress made in 2023 and the promising outlook for 2024 with expected clinical data from the TNG908 trial. The financial results reflect a company in the growth phase, investing heavily in its pipeline while maintaining a strong cash reserve to support its operations.\nFor more detailed information on Tango Therapeutics Inc (NASDAQ:TNGX)'s financial results and business highlights, investors and interested parties are encouraged to review the full 8-K filing.\nStay tuned to GuruFocus.com for further updates on Tango Therapeutics Inc (NASDAQ:TNGX) and other value investment opportunities.\n Explore the complete 8-K earnings release (here) from Tango Therapeutics Inc for further details. This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2420971582"}